Telix Pharmaceuticals Ltd has released a press release.
Telix Submits NDA for New Prostate Cancer Imaging Agent
Filed with ASX ·
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Telix Annual General Meeting - Presentation
- Telix Annual General Meeting - Chairman and CEO Addresses
- Telix Completes Proof-of-Concept Study for Alpha Therapy
- Telix has Filed Registration Statement for Proposed US IPO
- Telix Reports Q1 2024 Financial Performance
Later from Telix Pharmaceuticals
- Response to ASX Query
- ProstACT SELECT Study of TLX591 rADC Therapy - Positive rPFS
- Telix Completes TLX250-CDx (Zircaix) BLA Submission
- Telix Launches Proposed US IPO
- Trading Halt
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals